Valneva (NASDAQ:VALN – Get Free Report) and Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.
Earnings & Valuation
This table compares Valneva and Whitehawk Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Valneva | $142.94 million | 3.56 | -$130.33 million | ($2.11) | -2.53 |
| Whitehawk Therapeutics | $7.14 million | 25.87 | -$20.60 million | ($1.09) | -2.87 |
Volatility and Risk
Valneva has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.
Institutional & Insider Ownership
11.4% of Valneva shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Valneva and Whitehawk Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Valneva | -110.33% | -153.20% | -39.50% |
| Whitehawk Therapeutics | N/A | -55.66% | -51.60% |
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Valneva and Whitehawk Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Valneva | 2 | 0 | 1 | 0 | 1.67 |
| Whitehawk Therapeutics | 1 | 0 | 7 | 0 | 2.75 |
Valneva presently has a consensus price target of $9.30, suggesting a potential upside of 74.16%. Whitehawk Therapeutics has a consensus price target of $8.33, suggesting a potential upside of 166.24%. Given Whitehawk Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Whitehawk Therapeutics is more favorable than Valneva.
Summary
Whitehawk Therapeutics beats Valneva on 10 of the 13 factors compared between the two stocks.
About Valneva
Valneva is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. Founded in 2013 through the combination of Vivalis and Intercell, the company is headquartered in Saint-Herblain, France, and serves markets in Europe, North America and other regions through direct operations and commercial partners. Its marketed vaccines include IXIARO, for prevention of Japanese encephalitis, and DUKORAL, an oral vaccine for cholera. Valneva also developed IXCHIQ, a vaccine to prevent disease caused by chikungunya virus, which has received regulatory authorization in the United States and Europe.
About Whitehawk Therapeutics
Whitehawk Therapeutics is a biopharmaceutical company focused on developing treatments for cancer. Its work centers on oncology drug research and development. Publicly available information provides limited detail about the company’s specific products, development programs, operating geographies, or leadership.
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.
